Plain-English translation of NCT05674552 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
Phase 3 โ Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether exogenous ketone esters can help stop severe, uncontrolled seizures in children when standard seizure medications have failed. Ketones are a natural fuel your body can use, and researchers think they may help calm dangerous seizure activity very quickly. The study will compare children who receive the medication plus standard care to children who receive standard care alone.
When children have severe, life-threatening seizures that don't respond to first-line seizure medications, doctors need faster options. The traditional ketogenic diet takes time to work and is hard to use in emergencies. This medication could offer a faster way to achieve the benefits of ketones without the delay.
You likely qualify ifโฆ
You likely don't qualify ifโฆ
If you join this study, you will receive either the medication plus the standard emergency treatments for severe seizures, or standard treatments alone. The medication is given through a feeding tube. You will be monitored closely in the hospital to see how well the treatment works at stopping your seizures and how your body responds.
AI-generated summary from trial data ยท Jun 1, 2026 ยท Not medical advice
Egypt
Sponsor
Sohag University
Enrollment target
~50 participants
Started
January 2023
Primary completion
June 2025
This trial's estimated completion date has passed โ the record may not be fully up to date.
Age range
1 Year โ 10 Years
Last updated on clinicaltrials.gov in November 2024.
Reach out to the team running this trial. Response times vary โ some teams are faster than others.
Central contact
Elsayed M Abdelkreem, MD, PhD
Sohag University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first โ no email needed to get started.